Wednesday, 12 May 2021
Sunday, 25 April 2021
Infosys, bp collaborate to reduce emissions at campuses & cities
Infosys, bp collaborate to reduce emissions at campuses & cities
Infosys and bp have signed a memorandum of understanding (MoU) under which both companies intend to work together to develop an integrated Energy as-a -Service (EaaS) offering that will provide end-to-end management of a customers’ energy assets and services.
At 3.14 am, Infosys was trading at Rs. 1,351.15, up by 0.03%, with a volume of 7.03 lakh shares on the BSE.
Post Market- Markets stage smart recovery. Sensex up 375 points
Post Market- Markets stage smart recovery. Sensex up 375 points
Stocks in the news -
1. L&T Construction bagged order in the range of Rs. 1,000-2,500 cr to design & build one of the world's largest oil & gas supply bases
2. Subex launched HyperSense, an end-to-end augmented analytics platform that helps enterprises make faster
3. Filatex India Q4 net profit at Rs. 118.4 crore
Indian indices -
The benchmark indices ended higher on April 22, led by gains in metals and banking stocks amid positive global cues. The Sensex rose by 0.77% or 374.87 points to 48,080.67. The Nifty surged by 0.79% or 109.75 points to 14,406.15.
The market breadth was in favour of advances with an advance-decline ratio of 3:2.
Buzzing stocks on BSE -
1. Indiabulls Housing Finance (IBH) surged by 7.33% to Rs. 177.20, after it has entered into a strategic co-lending partnership with HDFC Ltd to offer housing loans to homebuyers at competitive rates.
2. Caplin Point Laboratories rose by 2.86% to Rs. 521.70, after the company said its subsidiary received a final approval from the US drug regulator for its Abbreviated New Drug Application, neostigmine methylsulfate injection.
3. Network18 Media & Investments rallied by 11.95% to Rs. 43.10, after consolidated net profit surged by 241.91% to Rs. 205.80 crore in Q4 FY21.
4. ICICI Securities jumped by 6.87% to Rs. 453.30, after the company's consolidated net profit soared by 111.4% to Rs. 329.47 crore in Q4 FY21.
Global Signals -
Asian stock markets rose on April 22, following an overnight bounce on Wall Street.
European markets surged on April 22, a global rebound in markets after days of negative sentiment.
Pre-Market- SGX Nifty slips by 93.50 points. Markets may open in red
Pre-Market- SGX Nifty slips by 93.50 points. Markets may open in red
Indian Indices -
Indian stock markets likely to open lower on April 23, following losses in global peers and worries over a continuous spike in coronavirus cases in the county.
SGX Nifty fell by 0.65% or 93.50 points to 14,308.50.
Market close:
Indian stock markets closed April 20, session in a negative zone as selling was seen in IT, banks and FMCG stocks. The Sensex fell by 0.44% or 243.62 points to 47,705.80. The Nifty slipped by 0.51% or 63.05 points to 14,296.40.
Global News -
Stocks in Asia-Pacific were mixed on April 23, following an overnight drop on Wall Street.
European stocks closed higher on April 22, as traders digested the European Central Bank’s latest monetary policy decision.
Stock Update – UltraTech Cement
Stock Update – UltraTech Cement
The cement industry is expected to see weak demand in April as key states like Maharashtra, Uttar Pradesh and Delhi have announced lockdowns (barring a leeway for essentials) led by rising COVID-19 cases.
Click here to know more about stock update.....
Dabur India: Stock update
Dabur India: Stock update
Dabur India Limited (Dabur) consistently registered strong double-digit volume growth of 17%-18% in Q2FY2021 and Q3FY2021. Strong volume growth can be attributed to robust demand for healthcare and ethical products and market share gains in categories such as oral care, shampoos, Chyawanprash, and honey.
Click here to know more about stock update....
Market Report: Markets trade in red. Sensex above 47,900
Market Report: Markets trade in red. Sensex above 47,900
Indian indices began the session on a weak note on April 23, tracking mixed global market and a continuous spike in coronavirus cases and stricter restrictions fuelled worries of more economic pain. At 9.24 am, Sensex fell by 0.21% or 138 points to 47,935. The Nifty slipped by 0.32% or 35 points to 14,371.
The losses in the market were mainly led by banking and IT stocks.
Asia-Pacific was mixed on April 23, following an overnight drop on Wall Street.
Rupee opens at 75.02/$
Rupee opens at 75.02/$
Indian rupee opened lower at 75.02 per dollar on April 23, against previous close of 74.95, amid selling seen in the domestic equity market.
On April 22, rupee ended lower by 7 paise at 74.95 per dollar against April 20 close of 74.88.
Alembic Pharma gets USFDA nod for Doxepin Hydrochloride Capsules
Alembic Pharma gets USFDA nod for Doxepin Hydrochloride Capsules
Alembic Pharmaceuticals received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Doxepin Hydrochloride Capsules USP, 10 mg, 25 mg, 50 mg, 75 mg and 100 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Sinequan Capsules 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg, of Pfizer Inc. (Pfizer). Doxepin Hydrochloride Capsules are recommended for the treatment of: i) Psychoneurotic patients with depression and/or anxiety, ii) Depression and/or anxiety associated with alcoholism (not to be taken concomitantly with alcohol), iii) Depression and/or anxiety associated with organic disease (the possibility of drug interaction should be considered if the patient is receiving other drugs concomitantly), iv) Psychotic depressive disorders with associated anxiety including involutional depression and manic-depressive disorders.
Doxepin Hydrochloride Capsules USP, 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg have an estimated market size of US$ 41 million for twelve months ending December 2020 according to IQVIA.
At 10.54 am, Alembic Pharmaceuticals was trading at Rs. 1,008.40, up by 0.47%, with a volume of 7506 lakh shares on the BSE.
Zydus Cadila receives final approval from USFDA for Propafenone Hydrochloride Extended-Release Capsules
Zydus Cadila receives final approval from USFDA for Propafenone Hydrochloride Extended-Release Capsules
Zydus Cadila has received final approval from the USFDA to market Propafenone Hydrochloride ExtendedRelease Capsules USP, 225 mg, 325 mg, and 425 mg (US RLD: Rythmol Capsules). Propafenone is known as an anti-arrhythmic drug. It works by blocking the activity of certain electrical signals in the heart that can
cause an irregular heartbeat.
The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad. The group now has 315 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.
Caplin Steriles gets USFDA approval for Prochlorperazine Edisylate Injectionn FY 2003-04
Caplin Steriles gets USFDA approval for Prochlorperazine Edisylate Injectionn FY 2003-04
Caplin Steriles, a Subsidiary Company of Caplin Point Laboratories Ltd, has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Prochlorperazine Edisylate Injection USP, 10 mg/2 mL (5 mg/mL) Vials presentations, a generic therapeutic equivalent version of (RLD), COMPAZINE Injection, of SmithKlineBeecham Corporation, USA.
Prochlorperazine Edisylate Injection is an antiemetic and is indicated for the control of severe nausea and vomiting. According to IQVIATM (IMS Health), Prochlorperazine Edisylate Injection had US sales data of approximately $17 million for the 12-month period ending Dec 2020.
At 11.41 am, Caplin Point Laboratories was trading at Rs. 525.45, up by 0.72%, with a volume of 0.38 lakh shares on the BSE.
Tata Elxsi Q4 net profit surges by 40% YoY
Tata Elxsi Q4 net profit surges by 40% YoY
Tata Elxsi reported Q4 earnings for the Quarter ended March 31, 2021:
Net profit surged by 40.3% YoY to Rs. 115.16 crore Vs Rs. 82.08 crore
Revenue from Operation rose by 18.1% YoY to Rs. 18.1% YoY to Rs. 518.39 crore Vs Rs. 438.88 crore
Midday Report: Markets trade flat. PSU banks rally
Midday Report: Markets trade flat. PSU banks rally
Indian stock markets are trading flat as gains in banking, metals and IT stocks were countered by losses in FMCG and pharma indices. At 12.49 pm, Sensex fell by 0.1% or 9 points to 48,062. The Nifty dipped by 0.04% or 5 points to 14,401.
Asia-Pacific was mixed on April 23, with the price of bitcoin tumbling below $50,000.
European markets opened slightly lower on April 23, as global stocks wither to end the week, with investors monitoring a slew of economic data and corporate earnings.
Pidilite Ind hikes stake in Cipy Poly Urethanes
Pidilite Ind hikes stake in Cipy Poly Urethanes
Pidilite Industries' subsidiary entity namely M/s. Cipy Poly Urethanes Pvt. Ltd. (CIPY), has increased from 70% to 100%, pursuant to the acquisition of the balance 28,249 equity shares from certain other shareholders, in accordance with the provisions of the shareholders agreement January 05, 2018. Consequent to this, CIPY is now a wholly owned subsidiary of the Company. The consideration of Rs. 60.49 crore (excluding certain contingent payment) has been paid in cash.
This transaction does not constitute a material transaction for the Company and it is not a related party transaction.
At 2.04 pm, Pidilite Industries was trading at Rs. 1,781, down by 0.20%, with a volume of 7341 shares on the BSE.
Ind Ra revises down India's FY22 GDP growth forecast to 10.1%
Ind Ra revises down India's FY22 GDP growth forecast to 10.1%
India Ratings and Research on April 23, revised down India’s FY22 real GDP growth forecast to 10.1%, from an earlier projection of 10.4%, citing the second wave of COVID-19 infections and slower pace of vaccination. At a time when large parts of the country are experiencing tremendous pressure on medical infrastructure, the agency said it expects the second wave to start subsiding by mid-May.
Earlier this month, the Reserve Bank maintained its 10.5 percent GDP growth estimate, but Governor Shaktikanta Das has flagged the rising cases as the biggest impediment to recovery.
Market update- Markets trade under pressure. Sensex plunges 250 points
Market update- Markets trade under pressure. Sensex plunges 250 points
Benchmark Indices were trading lower on April 23, dragged by selling in IT, pharma, FMCG, auto and metal stocks. At 2.34 pm, Sensex declined by 0.52% or 258 points to 47,819. The Nifty plunged by 0.54% or 87 points to 14,318.
Stocks in Asia-Pacific were mixed on April 23, with the price of bitcoin tumbling below $49,000.
European markets were little changed on April 23, as global stocks search for direction to end the week, with investors monitoring a slew of economic data and corporate earnings.
Zydus get DCGI nod for emergency use of Pegylated Interferon alpha-2b
Zydus get DCGI nod for emergency use of Pegylated Interferon alpha-2b
Zydus Cadila has received Restricted Emergency Use Approval from the Drug Controller General of India (DCGI) for the use of 'Virafin', Pegylated Interferon alpha-2b (PegIFN) in treating moderate COVID-19 infection in adults. A single dose subcutaneous regimen of the antiviral Virafin will make the treatment more convenient for the patients. When administered early on during COVID, Virafin will help patients recover faster and avoid much of the complications. Virafin will be available on the prescription of medical specialist for use in hospital/institutional setup.
Post Market - Sensex falls 202 points, Nifty ends below 14,350
Post Market - Sensex falls 202 points, Nifty ends below 14,350
Stocks in the news -
1. Alembic Pharma gets USFDA nod for Doxepin Hydrochloride Capsules, used to treat depression & anxiety
2. Caplin Steriles received USFDA approval for Prochlorperazine Edisylate Injection.
Indian indices -
The benchmark indices ended lower on April 23, dragged by selling in IT, FMCG and pharma stocks. The Sensex closed at 47,878.45, down 202.22 points, or 0.42%, while the Nifty was at 14,341.35, down 64.80 points, or 0.45%.
The market breadth was in favour of advances with an advance-decline ratio of 5:4.
Buzzing stocks on BSE -
1. Tata Elxsi jumped by 4.78% to Rs. 3,191.95, after the company's net profit increased by 9.5% to Rs 115.2 crore in Q4 FY21.
2. Cadila Healthcare rose by 3.43% to Rs. 571.20, after the company received emergency use approval from India's drug regulator for the use of Pegylated Interferon alpha-2b, 'Virafin' in treating moderate COVID-19 infection in adults.
Global Signals -
European markets were little changed on April 23. as global stocks search for direction to end the week, with investors monitoring a slew of economic data and corporate earnings.
Asian stock markets were mixed on April 23, after Wall Street fell following a report that President Joe Biden will propose raising taxes on wealthy investors.
HCL Technologies Q4 profit falls by 25.6% QoQ
HCL Technologies Q4 profit falls by 25.6% QoQ
HCL Technologies Q4 consolidated earnings for the Quarter ended March 31, 2021:
Consolidated net profit slipped by 25.6% QoQ to Rs. 2,962 crore Vs Rs. 3,982 crore
Revenue rose by 1.8% QoQ to Rs. 19,642 crore Vs. Rs. 19,302 crore
Revenue in dollar terms rose by 3% sequentially to $2,696 million in Q4FY21
EBIT fell by 9.9% QoQ to Rs. 3,980 crore Vs Rs. 4,416. crore
FY22 Guidance: Revenue expected to grow in double digits constant currency terms; EBIT margin expected to be between 19-21%.
Tata Elxsi: stock update
Tata Elxsi: stock update
Tata Elxsi Limited (TEL) impressed once again with continued beat in revenue and operating profitability. The company reported constant currency (CC) revenue growth of 9.1% q-o-q/15.2% y-o-y, ahead of our estimates, led by strong 5.5% q-o-q/12.5% y-o-y and 40.2% q-o-q/36.3% y-o-y growth in embedded product design (EPD) and industrial design and visualisation (IDV) businesses.
Click here to know more about stock update.....
HCL Tech: stock update
HCL Tech: stock update
HCL Technologies’ (HCL Tech) headline numbers remained below our expectations in Q4FY21 owing to higher-than-expected seasonal decline in product business, while order bookings, employee additions and higher dividend payments remained impressive.
Click here to know more about stock update.....
Stock Update: GNA Axles
Stock Update: GNA Axles
GNA Axles posted strong performance in Q4FY2021 with revenue growing by 72% y-o-y to Rs. 310crore, EBITDA margin stood at 15.6% improving 520 bps y-o-y, and PAT grew by 495% to Rs. 27.6crore.
Click here to know more about stock update.....
Market Report - Markets open higher. Sensex jumps 500 points
Indices opened higher on April 26, following gains in Asian peers amid strong global cues, even as India continued to report over 3 lakh Covid-19 cases. At 9.23 am, Sensex rose by 1.01% or 508 points to 48,397. The Nifty surged by 1.08% or 147 points to 14,489.
Asia-Pacific stocks were mixed on April 26, as investors monitor Covid situation in India.